# CD274 (PD-L1): Immune Checkpoint Signaling, Tumor Evasion, and Immunotherapy Targeting


## Key Takeaways

- CD274 (PD-L1) is a type I transmembrane glycoprotein that acts as a critical immune checkpoint ligand, binding to the PD-1 receptor on T cells to inhibit their activation and effector functions, thereby facilitating tumor immune evasion.
- Aberrant PD-L1 expression is driven by multiple mechanisms including *CD274* genomic amplification at locus 9p24.1, structural rearrangements, promoter hypomethylation, and transcriptional induction by inflammatory cytokines (e.g., IFN-γ via JAK-STAT) and oncogenic pathways (e.g., HIF-1α, TWIST1).
- The PD-1/PD-L1 axis is a major target in cancer immunotherapy, with monoclonal antibodies like atezolizumab, durvalumab, pembrolizumab, and nivolumab blocking this interaction to restore anti-tumor T-cell responses, leading to durable responses in various malignancies.
- Diagnostic assessment of PD-L1 expression for immunotherapy selection relies on immunohistochemistry (IHC) using specific antibody clones (e.g., 22C3, 28-8) and is complemented by genomic analyses such as FISH or NGS to detect *CD274* copy number alterations or rearrangements.
- Viral pathogens like KSHV, HPV, and EBV can upregulate PD-L1 expression through viral proteins (e.g., KSHV RTA, HPV E6/E7) that directly activate *CD274* transcription or modulate signaling pathways, contributing to viral persistence and immune evasion.
- Post-transcriptional regulation by microRNAs targeting the extensive 3' UTR of *CD274* mRNA and post-translational modifications, including glycosylation and ubiquitination, significantly influence PD-L1 protein stability and cell surface expression.

---

## Executive Summary & Key Metadata

CD274 encodes Programmed Death-Ligand 1 (PD-L1), a type I transmembrane glycoprotein of the B7/CD28 immunoglobulin superfamily. PD-L1 is the principal ligand for the Programmed Cell Death Protein 1 (PD-1, encoded by *PDCD1*) receptor, a critical negative regulator of T-cell activation, cytokine production, and cytolytic function. Beyond its canonical role in maintaining peripheral immune tolerance, PD-L1 is constitutively or inducibly overexpressed across a broad spectrum of human malignancies, where it functions as a primary mechanism of tumor immune evasion. The clinical blockade of the PD-1/PD-L1 axis with monoclonal antibodies has revolutionized oncology, producing durable responses in multiple cancer types. However, response rates are heterogeneous, and the molecular determinants of sensitivity—including *CD274* genomic amplification, copy number gain, structural rearrangements, promoter methylation status, and post-transcriptional regulation—remain areas of intensive investigation. This reference manual provides a comprehensive, biophysically detailed analysis of the *CD274* gene, its protein product, regulatory networks, pathogenic alterations, and therapeutic targeting.

| **Attribute** | **Value** |
|:---|:---|
| **HGNC Symbol** | CD274 |
| **UniProt Accession** | Q9NZQ7 |
| **Representative PDB ID** | 4ZQK (human PD-1/PD-L1 complex) |
| **Chromosomal Locus** | 9p24.1 |
| **Primary Molecular Function** | Immune checkpoint ligand; PD-1 receptor binding; inhibition of T-cell receptor signaling |
| **Disease & Pathology Associations** | Non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, triple-negative breast cancer, colorectal cancer, autoimmune diseases (SLE, multiple sclerosis), viral infections (KSHV, HPV) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The *CD274* gene is located on the short arm of chromosome 9 at band p24.1 (9p24.1), a genomic region of significant immunological and oncological interest. The locus is flanked by *JAK2* (Janus Kinase 2) and *PDCD1LG2* (Programmed Cell Death 1 Ligand 2, encoding PD-L2), forming a syntenic cluster of genes that are frequently co-amplified in cancer. The human *CD274* gene spans approximately 21.5 kilobases (kb) of genomic DNA on the plus strand and comprises seven exons and six introns. The canonical transcript (NM_014143.4) is 4,083 nucleotides in length, with a 5' untranslated region (UTR) of 92 nucleotides, a coding sequence (CDS) of 873 nucleotides, and a 3' UTR of 3,118 nucleotides. The unusually long 3' UTR is a critical regulatory hub, containing multiple microRNA (miRNA) response elements, AU-rich elements (AREs), and structural variation hotspots that modulate mRNA stability and translational efficiency.

The promoter region of *CD274* lacks a canonical TATA box but contains multiple GC-rich Sp1 binding sites, interferon-stimulated response elements (ISREs), and gamma-activated sequences (GAS). These cis-regulatory elements enable rapid transcriptional induction by interferons (IFN-α, IFN-β, IFN-γ) and other inflammatory cytokines. The promoter also harbors binding sites for signal transducer and activator of transcription 3 (STAT3), nuclear factor-κB (NF-κB), hypoxia-inducible factor-1α (HIF-1α), and activator protein-1 (AP-1), reflecting the convergence of multiple oncogenic and inflammatory signaling pathways on *CD274* transcription.

### 1.2 Enhancer Elements and Chromatin Architecture

High-coverage whole-genome sequencing analyses from the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium have identified recurrent structural variants (SVs) that reposition distal enhancer elements into proximity with the *CD274* promoter, leading to transcriptional dysregulation in the absence of coding-region mutations. These SV-mediated cis-regulatory alterations, including tandem duplications and inversions, are particularly prevalent in diffuse large B-cell lymphoma (DLBCL), gastric adenocarcinoma, and squamous cell lung carcinoma. The 9p24.1 region also contains a topologically associating domain (TAD) boundary that, when disrupted by somatic copy number alterations, can lead to enhancer hijacking and aberrant PD-L1 overexpression.

Epigenetic regulation of the *CD274* locus is a major determinant of expression variability. The promoter and first exon contain a CpG island of approximately 1.2 kb. DNA methylation at specific CpG dinucleotides within this island inversely correlates with PD-L1 mRNA and protein expression across multiple tumor types, including acute myeloid leukemia (AML), bladder cancer, head and neck squamous cell carcinoma (HNSCC), and triple-negative breast cancer (TNBC). Promoter hypomethylation is associated with increased PD-L1 expression and, in metastatic urothelial carcinoma, predicts response to immune checkpoint blockade (ICB). Conversely, hypermethylation of the *CD274* promoter is a mechanism of transcriptional silencing and intrinsic resistance to anti-PD-1/PD-L1 therapy.

Histone modifications also play a central role. The male-specific lethal (MSL) complex, which catalyzes histone H4 lysine 16 acetylation (H4K16ac) via its KAT8/MOF subunit, has been shown to bind the *CD274* promoter and activate transcription. Loss of the pioneer transcription factor FOXA1, a frequent event in bladder cancer, results in genome-wide epigenetic reprogramming characterized by increased H4K16ac and enhanced interferon-response gene activation, including *CD274*.

### 1.3 Transcription Factor Binding and Transcriptional Regulation

The transcriptional regulation of *CD274* is orchestrated by a complex network of constitutive and inducible transcription factors. The JAK-STAT pathway is the dominant inducer of PD-L1 expression. IFN-γ binding to its receptor activates JAK1/JAK2, leading to STAT1 and STAT3 phosphorylation, homodimerization, and nuclear translocation. Phosphorylated STAT1/STAT3 bind to GAS elements in the *CD274* promoter, driving robust transcriptional activation. In myeloproliferative neoplasms (MPNs), constitutive JAK-STAT activation due to driver mutations (e.g., *JAK2* V617F) results in elevated PD-L1 expression, contributing to immune escape.

Additional transcription factors implicated in *CD274* regulation include:

- **TWIST1**: A master regulator of epithelial-mesenchymal transition (EMT), TWIST1 directly binds the *CD274* promoter and drives PD-L1 expression in breast cancer cells, linking EMT programs to immune evasion.
- **YAP/TAZ**: The Hippo pathway effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) bind TEAD family transcription factors to activate *CD274* transcription in malignant pleural mesothelioma.
- **HIF-1α**: Under hypoxic conditions, HIF-1α binds hypoxia-response elements (HREs) in the *CD274* promoter, upregulating PD-L1 expression in the tumor microenvironment.
- **NF-κB**: Inflammatory stimuli activate NF-κB, which cooperates with STAT3 to induce *CD274* transcription.
- **AP-1 (Jun/Fos)**: Growth factor signaling through MAPK pathways activates AP-1 complexes that bind the *CD274* promoter.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *CD274* generates multiple transcript variants with distinct functional properties. The canonical isoform (isoform 1, NP_054862.1) encodes the full-length 290-amino acid type I transmembrane protein. A soluble isoform (sPD-L1) is generated by alternative splicing that removes the transmembrane domain-encoding exon, producing a secreted protein that retains PD-1 binding capacity. Elevated serum levels of sPD-L1 are associated with poor prognosis in several cancers and may act as a "decoy" to sequester anti-PD-L1 therapeutic antibodies.

A second alternatively spliced variant lacking exon 3 (which encodes the IgV-like domain) produces a truncated protein incapable of binding PD-1. This isoform may function as a dominant-negative regulator of PD-L1 signaling. Additionally, the 3' UTR of *CD274* is subject to alternative polyadenylation, generating transcripts with variable 3' UTR lengths that differ in miRNA binding site availability and mRNA stability.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PD-L1 protein (UniProt Q9NZQ7) is a 290-amino acid type I transmembrane glycoprotein with a molecular weight of approximately 33 kDa (33,278 Da) for the unmodified polypeptide. Post-translational modifications, including N-linked glycosylation at Asn192, Asn200, and Asn219, increase the apparent molecular weight to 45–55 kDa on SDS-PAGE. The protein is organized into distinct structural and functional domains:

| **Domain** | **Residues** | **Function** |
|:---|:---|:---|
| **Signal peptide** | 1–18 | Directs co-translational translocation to the ER membrane |
| **Extracellular IgV-like domain** | 19–127 | PD-1 binding; primary interface for immune checkpoint interaction |
| **Extracellular IgC-like domain** | 128–225 | Structural stabilization; dimerization interface |
| **Transmembrane domain** | 226–248 | Hydrophobic α-helix anchoring the protein in the plasma membrane |
| **Intracellular cytoplasmic tail** | 249–290 | Signal transduction; contains putative phosphorylation sites and sorting motifs |

### 2.2 Three-Dimensional Structure of the PD-1/PD-L1 Complex

The high-resolution crystal structure of the human PD-1/PD-L1 complex (PDB: 4ZQK) reveals the molecular basis of immune checkpoint signaling. The IgV-like domain of PD-L1 (residues 19–127) adopts a canonical immunoglobulin fold consisting of a two-layer β-sandwich: one β-sheet formed by strands A, B, E, and D, and the opposite sheet formed by strands C, C', C'', F, and G. The PD-1 binding interface is located on the front sheet (GFCC'C'' face) of the IgV domain, a region structurally homologous to the CD80/CD86 binding sites on other B7 family members.

The binding interface buries approximately 1,970 Ų of solvent-accessible surface area and is dominated by hydrophobic interactions, complemented by a network of hydrogen bonds and salt bridges. Key residues on PD-L1 contributing to PD-1 binding include:

- **Tyr56** and **Arg113**: Form a critical hydrogen bond network with PD-1 residues.
- **Met115** and **Ala121**: Contribute to the hydrophobic core of the interface.
- **Asp122** and **Lys124**: Participate in electrostatic interactions with PD-1's FG loop.

The PD-1 binding site on PD-L1 is conformationally rigid, which has facilitated the development of small-molecule inhibitors and peptide mimetics that target this interface. Non-synonymous single nucleotide polymorphisms (nsSNPs) within the IgV domain can significantly alter binding affinity. For example, in silico structural analyses have identified that mutations at positions 54, 56, and 113 disrupt the hydrogen bonding network and reduce PD-1 binding affinity, potentially affecting immune checkpoint function.

### 2.3 Oligomeric State and Membrane Organization

PD-L1 exists in a dynamic equilibrium between monomeric and homodimeric states on the cell surface. The IgC-like domain (residues 128–225) mediates homodimerization through a side-by-side interaction, forming a "V-shaped" dimer that presents two PD-1 binding sites. Dimerization is not required for PD-1 binding but may enhance avidity and signaling potency. The transmembrane domain contains a GxxxG dimerization motif, which promotes helix-helix association in the lipid bilayer and may stabilize the dimeric state.

### 2.4 Post-Translational Modifications and Structural Dynamics

N-linked glycosylation at Asn192, Asn200, and Asn219 within the IgC-like domain is essential for proper protein folding, stability, and cell surface expression. Glycosylation also shields the protein from proteolytic degradation and modulates interactions with other cell surface receptors. The cytoplasmic tail contains a putative protein kinase C (PKC) phosphorylation site (Ser279) and a Bcl-2 homology 3 (BH3)-like domain, which has been implicated in apoptosis resistance.

Recent structural studies have revealed that PD-L1 can undergo conformational changes upon ligand binding, with the IgV domain rotating relative to the IgC domain. This "clamshell" motion may be important for signal transduction across the membrane.

> **[Interactive 3D Protein Visualizer: Load CD274 (PDB: 4ZQK)](/tools/protein-structure-viewer?source=direct&pdbId=4ZQK)**

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The PD-1/PD-L1 Axis: Mechanistic Basis of T-Cell Inhibition

The primary function of PD-L1 is to engage PD-1 (CD279) on the surface of activated T cells, B cells, natural killer (NK) cells, and myeloid cells, delivering an inhibitory signal that suppresses effector functions. The interaction between PD-L1 and PD-1 occurs in *trans* (between two different cells) at the immunological synapse, where it outcompetes the costimulatory interaction between CD28 and CD80/CD86 due to its higher affinity (Kd ≈ 0.4–2.5 µM for PD-1/PD-L1 vs. Kd ≈ 4–20 µM for CD28/CD80).

Upon PD-L1 binding, PD-1 undergoes conformational changes that promote the recruitment of the Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 2 (SHP-2) to its immunoreceptor tyrosine-based switch motif (ITSM) and immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic tail. SHP-2 dephosphorylates key signaling molecules in the T-cell receptor (TCR) signaling cascade, including:

- **ZAP-70**: Dephosphorylation at Tyr319 inactivates this kinase, blocking downstream signaling.
- **CD3ζ**: Dephosphorylation of the ITAMs prevents TCR signal initiation.
- **PI3K p85 subunit**: Dephosphorylation inhibits the PI3K-AKT-mTOR pathway, reducing cell survival and proliferation.
- **ERK1/2**: Dephosphorylation attenuates MAPK signaling, impairing cytokine production.

The net effect is the inhibition of T-cell proliferation, reduced production of IL-2, IFN-γ, and TNF-α, and decreased cytolytic activity. Chronic PD-1 engagement drives T-cell exhaustion, a state characterized by sustained upregulation of inhibitory receptors (TIM-3, LAG-3, [TIGIT](/knowledge/bioinformatics/genes/immunology-checkpoints/tigit-gene-structure-function-pathway)), loss of effector function, and epigenetic remodeling of effector gene loci.

### 3.2 PD-L1 Reverse Signaling in Tumor Cells

Beyond its role as a ligand for PD-1, PD-L1 can transmit intrinsic "reverse" signals into the tumor cell. Engagement of PD-L1 by PD-1 or by antibody cross-linking activates signaling pathways that promote tumor cell survival, proliferation, and resistance to apoptosis. Key mechanisms include:

- **AKT/mTOR activation**: PD-L1 engagement activates PI3K/AKT signaling, promoting cell survival and metabolic reprogramming.
- **mTOR-TFEB pathway**: PD-L1 regulates lysosomal biogenesis and autophagy through the mTOR-TFEB axis. Tumorous cholesterol biosynthesis inhibits mTOR-TFEB-mediated lysosomal degradation of PD-L1, creating a positive feedback loop that sustains high PD-L1 surface expression.
- **Interferon-γ resistance**: PD-L1 signaling upregulates the expression of suppressor of cytokine signaling 1 (SOCS1), which inhibits JAK-STAT signaling and confers resistance to IFN-γ-mediated growth arrest.

### 3.3 Regulation of PD-L1 Expression: A Multi-Layered Network

#### 3.3.1 Transcriptional Regulation

As detailed in Section 1.3, *CD274* transcription is induced by IFN-γ (via JAK-STAT), hypoxia (via HIF-1α), and oncogenic signaling pathways (via MYC, RAS, and PI3K-AKT). The transcription factor TWIST1 directly activates *CD274* transcription in breast cancer cells, linking EMT to immune evasion. The MSL complex, through H4K16ac, epigenetically activates *CD274* expression.

#### 3.3.2 Post-Transcriptional Regulation by MicroRNAs

The 3' UTR of *CD274* is a major target for miRNA-mediated repression. Multiple miRNAs have been validated to directly bind the *CD274* 3' UTR and downregulate PD-L1 expression:

| **miRNA** | **Cancer Type** | **Effect** | **Reference** |
|:---|:---|:---|:---|
| **miR-138-5p** | Non-small cell lung cancer | Downregulates PD-L1, enhances T-cell-mediated killing | |
| **miR-195/miR-497** | Triple-negative breast cancer | Downregulates PD-L1, reduces immune evasion | |
| **miR-570-3p** | Triple-negative breast cancer | Downregulates PD-L1 via PI3K/AKT/mTOR pathway | |
| **miR-15a-5p/miR-16-5p** | Chronic lymphocytic leukemia | Indirectly regulate PD-1/PD-L1 axis | |
| **miR-155** | Various | Context-dependent regulation of PD-L1 | |

Polymorphisms in the *CD274* 3' UTR can disrupt miRNA binding sites, leading to increased PD-L1 expression. For example, the rs4143815 G allele disrupts a miR-570 binding site, resulting in elevated PD-L1 expression and increased risk of non-small cell lung cancer.

#### 3.3.3 Post-Translational Regulation

PD-L1 protein stability is regulated by ubiquitination, deubiquitination, and lysosomal degradation. The E3 ubiquitin ligase PRKN (Parkin) ubiquitinates PD-L1 at mitochondria-ER contact sites (MERCs), targeting it for proteasomal degradation and enhancing anti-tumor immunity in cervical cancer. Conversely, the deubiquitinase USP22 removes ubiquitin chains from PD-L1, stabilizing the protein. The CMTM6 (CKLF-like MARVEL transmembrane domain-containing protein 6) binds PD-L1 at the plasma membrane and protects it from lysosomal degradation, maintaining steady-state surface expression.

### 3.4 Protein-Protein Interaction Networks

The PD-L1 interactome extends beyond PD-1. Key protein-protein interactions include:

- **CD80 (B7-1)**: PD-L1 can bind CD80 in *trans* and *cis*, functioning as a bidirectional inhibitory checkpoint. The PD-L1/CD80 interaction on antigen-presenting cells delivers an inhibitory signal to T cells independently of PD-1.
- **CMTM6**: A chaperone that stabilizes PD-L1 at the cell surface by preventing its ubiquitination and lysosomal degradation.
- **RACK1**: A scaffolding protein that promotes PD-L1 ubiquitination and degradation.
- **STING**: The stimulator of interferon genes (STING) pathway is functionally linked to PD-L1 expression, with STING activation promoting IFN-dependent PD-L1 upregulation.

```mermaid
sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant TCell as "T Cell"
    participant Tumor as "Tumor Cell"
    participant PD1 as "PD-1 Receptor"
    participant PDL1 as "PD-L1 (CD274)"
    participant SHP2 as "SHP-2 Phosphatase"
    participant TCR as "TCR Complex"
    participant ZAP70 as "ZAP-70 Kinase"
    Note over Tumor, TCell: Immune Evasion via PD-1/PD-L1 Axis
    Tumor->>PDL1: Express PD-L1 on surface
    TCell->>PD1: Express PD-1 upon activation
    PDL1->>PD1: Bind PD-1 (Kd ≈ 0.4-2.5 µM)
    PD1->>SHP2: Recruit SHP-2 to ITSM/ITIM
    SHP2->>ZAP70: Dephosphorylate ZAP-70 (Tyr319)
    SHP2->>TCR: Dephosphorylate CD3ζ ITAMs
    ZAP70-->>TCR: Inactivate TCR signaling
    Note over TCell: Inhibition of proliferation<br/>Reduced IL-2, IFN-γ, TNF-α<br/>T-cell exhaustion
    APC->>Tumor: Present tumor antigens
    TCR->>Tumor: Recognize MHC-peptide complex
    Note over TCell, Tumor: Checkpoint blockade (anti-PD-1/PD-L1)<br/>restores T-cell effector function
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations and Copy Number Alterations

#### 4.1.1 Short Variant Mutations

Pan-cancer analyses of *CD274* mutations across 314,631 patient samples have revealed that short variant (SV) mutations in *CD274* are relatively rare, occurring in approximately 1–3% of tumors, but are enriched in specific cancer types including melanoma, lung cancer, and DLBCL. The majority of SV mutations are missense mutations located in the extracellular IgV domain, with hotspots at residues Arg113, Asp122, and Tyr56—all of which are critical for PD-1 binding. In silico structural modeling predicts that these mutations disrupt the PD-1/PD-L1 interface, potentially reducing binding affinity and altering the efficacy of ICB therapy.

Frameshift and nonsense mutations in *CD274* are less common but have been reported in microsatellite instability-high (MSI-H) colorectal cancer and endometrial cancer, where they may generate neoantigens that enhance immunogenicity.

#### 4.1.2 Copy Number Amplification and Gain

*CD274* copy number amplification (CNA) is a well-established mechanism of PD-L1 overexpression and a predictive biomarker for ICB response. The 9p24.1 amplicon, which includes *CD274*, *PDCD1LG2*, and *JAK2*, is a hallmark of classical Hodgkin lymphoma (cHL), where it is present in nearly 100% of cases. In cHL, the amplification of *JAK2* in cis with *CD274* creates a feed-forward loop: JAK2 amplifies the IFN-γ signaling pathway, which in turn drives *CD274* transcription.

Beyond cHL, *CD274* amplification is observed across a wide spectrum of solid tumors:

| **Cancer Type** | **Frequency of CD274 Amplification** | **Clinical Significance** | **Reference** |
|:---|:---|:---|:---|
| **Non-small cell lung cancer (NSCLC)** | 3–10% | High TPS, response to pembrolizumab | |
| **Small-cell lung cancer (SCLC)** | ~2% | Potential biomarker for ICB | |
| **Triple-negative breast cancer (TNBC)** | 5–10% | Associated with TILs and ICB response | |
| **Squamous cell carcinoma of the oral cavity** | ~20% | High PD-L1 protein expression | |
| **Colorectal cancer** | 2–5% | MSI-H tumors enriched | |
| **Soft-tissue sarcoma** | ~5% | Candidate predictor for ICB | |
| **Urothelial carcinoma** | 5–10% | Response to atezolizumab | |
| **Melanoma** | 5–8% | Correlates with PD-L1 expression | |

The relationship between *CD274* amplification and PD-L1 protein expression is not linear. Focal, high-level amplifications (copy number ≥ 6) are strongly associated with high PD-L1 tumor proportion score (TPS), whereas low-level gains (copy number 3–5) show variable protein expression. This discordance is attributed to the influence of tumor microenvironmental factors, particularly IFN-γ signaling, on PD-L1 expression.

#### 4.1.3 Structural Rearrangements

*CD274* rearrangements, including translocations and inversions, are rare but recurrent events across multiple cancer types. A pan-cancer analysis of 283,050 patient samples identified *CD274* rearrangements in 0.3% of cases, with the highest prevalence in DLBCL (2.1%), gastric cancer (1.1%), and breast cancer (0.7%). These rearrangements frequently juxtapose the *CD274* coding sequence with strong enhancer elements from other genes, leading to constitutive PD-L1 overexpression. Patients with *CD274* rearrangements show high PD-L1 protein expression and favorable responses to ICB therapy.

#### 4.1.4 Structural Variants in the 3' UTR

Structural variations in the *CD274* 3' UTR, including deletions and insertions, can disrupt miRNA binding sites and AREs, leading to increased mRNA stability and elevated PD-L1 expression. Non-invasive plasma testing for *CD274* UTR structural variations by next-generation sequencing has been proposed as a liquid biopsy approach to identify patients likely to benefit from ICB.

### 4.2 Germline Polymorphisms and Disease Susceptibility

#### 4.2.1 Single Nucleotide Polymorphisms (SNPs)

Multiple germline SNPs in *CD274* have been associated with susceptibility to autoimmune diseases and cancer:

| **SNP** | **Location** | **Disease Association** | **Reference** |
|:---|:---|:---|:---|
| **rs4143815** | 3' UTR | NSCLC risk; PD-L1 expression levels | |
| **rs2297136** | 3' UTR | Systemic lupus erythematosus (SLE) risk | |
| **rs822339** | Intron 1 | Multiple sclerosis susceptibility | |
| **rs2890658** | Intron 2 | Lung cancer risk (LUAD vs. LUSC) | |
| **rs17718883** | 5' UTR | Polycystic ovary syndrome (PCOS) | |
| **rs10815225** | Intron 4 | Diffuse large B-cell lymphoma prognosis | |

The rs4143815 SNP, located in the 3' UTR, disrupts a miR-570 binding site. The G allele is associated with higher PD-L1 expression and increased risk of NSCLC. In a Chinese Han population, the rs2297136 polymorphism was significantly associated with SLE susceptibility, with the minor allele conferring protection. Multifactor dimensionality reduction analyses have identified synergistic interactions between *CD274* SNPs and variants in *BTN3A1*, *SHP2*, and *STAT3* that collectively modulate SLE risk.

#### 4.2.2 Haplotype Analysis

Haplotype analysis of *CD274* has revealed that specific combinations of SNPs in the promoter and 3' UTR are associated with differential PD-L1 expression and clinical outcomes. In extensive-stage small-cell lung cancer (ES-SCLC), *CD274* polymorphisms were predictive of response to first-line platinum-based chemotherapy, suggesting that inherited genetic variation in immune checkpoint genes can modulate chemosensitivity.

### 4.3 Epigenetic Alterations

#### 4.3.1 Promoter Methylation

*CD274* promoter methylation is a dynamic and clinically relevant epigenetic mark. In AML, high *CD274* promoter methylation is associated with reduced PD-L1 expression and worse overall survival. In bladder cancer, *CD274* methylation is an independent predictor of patient survival. In metastatic urothelial carcinoma, promoter hypomethylation predicts response to atezolizumab, suggesting that methylation status could serve as a companion diagnostic for ICB.

In HNSCC, *CD274* and *PDCD1LG2* promoter methylation is associated with HPV infection status and transcriptional repression. HPV-positive tumors exhibit lower PD-L1 methylation and higher PD-L1 expression, which may contribute to their favorable response to ICB.

#### 4.3.2 Histone Modifications

The MSL complex-mediated H4K16ac at the *CD274* promoter is an activating mark that promotes transcription. Loss of FOXA1, a pioneer factor, leads to increased H4K16ac at the *CD274* locus and upregulation of PD-L1 in bladder cancer.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical interpretation of *CD274* alterations requires integration of multiple assay modalities:

- **Immunohistochemistry (IHC)**: PD-L1 protein expression is quantified using the Tumor Proportion Score (TPS) for NSCLC, the Combined Positive Score (CPS) for gastric cancer and urothelial carcinoma, and the immune cell (IC) score for TNBC. Multiple antibody clones (22C3, 28-8, SP142, SP263) are FDA-approved, but they exhibit variable sensitivity and specificity.
- **Fluorescence in situ hybridization (FISH)**: Detects *CD274* copy number alterations and rearrangements on formalin-fixed, paraffin-embedded (FFPE) tissue.
- **Next-generation sequencing (NGS)**: Comprehensive genomic profiling (CGP) detects *CD274* SV mutations, CNAs, and rearrangements. The presence of *CD274* amplification is a strong predictor of ICB response across multiple tumor types.
- **Quantitative RT-PCR (qRT-PCR)**: *CD274* mRNA expression correlates with PD-L1 IHC and may serve as a complementary diagnostic.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV, also known as Human Herpesvirus 8 (HHV-8), is the etiologic agent of Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman disease. KSHV has evolved multiple strategies to evade the host immune system, including the upregulation of PD-L1. The KSHV replication and transcription activator (RTA) protein directly binds to the *CD274* promoter and activates its transcription. RTA is the master switch for KSHV lytic reactivation, and its ability to transactivate *CD274* ensures that infected cells are protected from T-cell-mediated killing during lytic replication.

In PEL cells, PD-L1 is constitutively overexpressed, contributing to the immunosuppressive tumor microenvironment. The 9p24.1 amplicon, which includes *CD274*, is also present in a subset of PEL cases, further amplifying PD-L1 expression.

### 5.2 Human Papillomavirus (HPV)

In head and neck squamous cell carcinoma (HNSCC), HPV infection is associated with higher PD-L1 expression. Mechanistically, the HPV E6 and E7 oncoproteins activate the PI3K-AKT pathway and upregulate HIF-1α, which in turn induces *CD274* transcription. HPV-positive HNSCC tumors also exhibit lower *CD274* promoter methylation, contributing to higher PD-L1 expression. These tumors are more responsive to ICB therapy, likely due to the combination of high PD-L1 expression and high [tumor mutational burden](/knowledge/bioinformatics/tumor-mutational-burden-tmb-and-computational-scoring) from viral antigens.

### 5.3 Epstein-Barr Virus (EBV)

EBV is associated with several malignancies, including Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric cancer. In EBV-positive gastric cancer, the *CD274* locus is frequently amplified, and PD-L1 is highly expressed. The EBV-encoded latent membrane protein 1 (LMP1) activates NF-κB and JAK-STAT signaling, both of which induce *CD274* transcription. EBV-positive gastric cancers show high response rates to PD-1 blockade, and *CD274* amplification is a defining feature of this molecular subtype.

### 5.4 Other Viral Pathogens

- **Hepatitis B and C viruses (HBV/HCV)**: Chronic HBV and HCV infections upregulate PD-L1 on hepatocytes and immune cells, contributing to T-cell exhaustion and viral persistence. PD-L1 blockade is being explored as an adjunct to antiviral therapy.
- **Human T-cell leukemia virus type 1 (HTLV-1)**: The HTLV-1 Tax protein transactivates the *CD274* promoter, leading to PD-L1 overexpression in adult T-cell leukemia/lymphoma (ATLL) cells.
- **SARS-CoV-2**: Severe COVID-19 is associated with T-cell exhaustion and elevated PD-L1 expression on monocytes and T cells, suggesting that the PD-1/PD-L1 axis contributes to the immunopathology of severe infection.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Monoclonal Antibodies Targeting PD-L1

| **Drug** | **Target** | **Isotype** | **FDA-Approved Indications** | **Key Clinical Data** |
|:---|:---|:---|:---|:---|
| **Atezolizumab (Tecentriq)** | PD-L1 | Humanized IgG1 (engineered Fc) | NSCLC, SCLC, TNBC, urothelial carcinoma, HCC | Phase Ib trial in mCRC with FOLFOX/bevacizumab showed clinical activity |
| **Durvalumab (Imfinzi)** | PD-L1 | Human IgG1 (engineered Fc) | NSCLC (consolidation after chemoradiation), SCLC, biliary tract cancer | Improved OS in stage III NSCLC |
| **Avelumab (Bavencio)** | PD-L1 | Human IgG1 (wild-type Fc) | Merkel cell carcinoma, urothelial carcinoma, RCC | First FDA-approved for Merkel cell carcinoma |

These antibodies block the PD-1/PD-L1 interaction, restoring T-cell effector function. The engineered Fc regions of atezolizumab and durvalumab (L234A/L235A/P329G mutations) eliminate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), minimizing depletion of PD-L1-expressing immune cells.

### 6.2 FDA-Approved Monoclonal Antibodies Targeting PD-1

| **Drug** | **Target** | **Isotype** | **FDA-Approved Indications** |
|:---|:---|:---|:---|
| **Pembrolizumab (Keytruda)** | PD-1 | Humanized IgG4 | Melanoma, NSCLC, HNSCC, cHL, urothelial carcinoma, MSI-H cancers, TNBC, etc. |
| **Nivolumab (Opdivo)** | PD-1 | Human IgG4 | Melanoma, NSCLC, RCC, cHL, HNSCC, urothelial carcinoma, MSI-H cancers, etc. |
| **Cemiplimab (Libtayo)** | PD-1 | Human IgG4 | Cutaneous squamous cell carcinoma, NSCLC, basal cell carcinoma |

### 6.3 Investigational Small-Molecule Inhibitors

The PD-1/PD-L1 interaction is mediated by a relatively flat, hydrophobic interface, which historically made it challenging to target with small molecules. However, several classes of small-molecule inhibitors have been developed:

- **BMS-202 and BMS-8**: These biphenyl-based compounds bind to the PD-L1 IgV domain and induce dimerization of PD-L1, which sterically blocks PD-1 binding. They have shown efficacy in preclinical models.
- **CA-170**: An orally bioavailable small molecule that targets both PD-L1 and VISTA (V-domain Ig suppressor of T-cell activation). It has completed Phase I clinical trials.
- **INCB086550**: An orally bioavailable PD-L1 inhibitor developed

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)